Anti-D Administration at 28 Weeks Based on Indirect Coombs Test Results
If the indirect Coombs test (ICT) is negative at 28 weeks, you should give anti-D immunoglobulin; if the ICT is positive at 28 weeks, you should still give anti-D immunoglobulin unless the woman is already alloimmunized (has true anti-D antibodies from prior sensitization).
Understanding the Clinical Scenario
The indirect Coombs test status at 28 weeks determines your interpretation, not your decision to give prophylaxis:
When ICT is Negative at 28 Weeks
- Give anti-D immunoglobulin routinely at 28 weeks' gestation to all RhD-negative, non-sensitized women carrying an RhD-positive fetus (or when fetal blood type is unknown) 1.
- This antenatal prophylaxis reduced alloimmunization rates by 90% when added to postpartum-only programs, decreasing fetal mortality from Rh hemolytic disease from 120 per 100,000 live births to 1.5 per 100,000 1.
- The standard dose is 300 μg (1500 IU) intramuscularly or intravenously 2.
When ICT is Positive at 28 Weeks
This requires careful interpretation because a positive ICT at 28 weeks can mean two very different things:
Scenario 1: Passive Anti-D from Prior Prophylaxis
- If the woman received anti-D for a sensitizing event earlier in pregnancy (bleeding, trauma, invasive procedure), the ICT will be positive from the passive antibodies you gave her 3, 4.
- These passive antibodies are detectable by ICT in 85-97% of women for 4-11 weeks after administration, with titers typically ≤1:8 to 1:16 3.
- In this case, still give the routine 28-week dose because passive antibodies wane over time, and you need coverage through delivery 3, 2.
Scenario 2: True Alloimmunization (Sensitization)
- If the woman has developed true anti-D antibodies from prior sensitization (failed prophylaxis, missed dose, or sensitization before prophylaxis was available), the ICT will also be positive.
- In this case, anti-D prophylaxis is futile because she is already producing her own antibodies—the horse has left the barn.
- However, she requires specialized fetal medicine monitoring for hemolytic disease of the fetus and newborn (HDFN) with serial middle cerebral artery Doppler assessments 5, 6.
How to Distinguish Between Passive and Active Antibodies
Key distinguishing features:
Timing and History
- Review whether anti-D was given earlier in pregnancy (first trimester bleeding, trauma, amniocentesis, etc.)
- If yes, and the ICT is positive within 4-11 weeks of that dose, it's likely passive antibodies 3
Antibody Titer
- Passive anti-D from prophylaxis typically produces titers ≤1:8 by standard ICT or ≤1:16 by more sensitive methods 3
- True alloimmunization often produces higher and rising titers, though this is not absolute
Serial Testing
- Passive antibodies decline over weeks; true alloimmunization shows stable or rising titers
- If uncertain, repeat testing in 2-4 weeks can clarify
Clinical Context
- First pregnancy with no prior sensitizing events = passive antibodies more likely if anti-D was given
- History of prior RhD-positive pregnancy without adequate prophylaxis = true alloimmunization more likely
The Critical Clinical Algorithm
At 28 weeks' gestation in an RhD-negative woman:
If ICT is negative:
- Give anti-D 300 μg immediately
- No further investigation needed
If ICT is positive:
- Review history: Was anti-D given earlier in this pregnancy?
- If YES (within past 4-11 weeks): Likely passive antibodies
- If NO (no prior anti-D this pregnancy): Likely true alloimmunization
- Review history: Was anti-D given earlier in this pregnancy?
Common Pitfalls to Avoid
Pitfall 1: Withholding 28-week anti-D because ICT is positive from earlier prophylaxis
- This leaves the woman unprotected in late pregnancy when fetomaternal hemorrhage risk is highest (29% of pregnancies show fetal cells in maternal circulation in third trimester) 1.
- Nearly two-thirds of women have undetectable anti-D at delivery when prophylaxis is given only at 28 weeks, especially if delivery occurs >10 weeks later 4, 7.
Pitfall 2: Assuming all positive ICT results at 28 weeks represent sensitization
- This leads to unnecessary anxiety, inappropriate withholding of prophylaxis, and excessive fetal monitoring 3.
Pitfall 3: Failing to give postpartum anti-D after detecting passive antibodies
- Even when anti-D is detectable at delivery from antenatal prophylaxis, postpartum anti-D must still be given if the baby is RhD-positive 3, 2.
- The detectable antibodies may be insufficient to cover the larger fetomaternal hemorrhage that occurs at delivery (50% of postpartum patients have fetal cells in circulation) 1.
Pitfall 4: Not testing for fetomaternal hemorrhage volume at delivery
- Standard 300 μg dose covers only 15 mL of fetal red blood cells (30 mL whole fetal blood) 2.
- Larger hemorrhages (especially with placental abruption, trauma, or manual placental removal) require additional anti-D: 10 μg per additional 0.5 mL fetal RBCs 2, 8.
The Bottom Line for Clinical Practice
The indirect Coombs test at 28 weeks does not determine whether to give anti-D—it helps you interpret what a positive result means. Unless you can definitively establish true alloimmunization (no prior anti-D given this pregnancy + positive ICT), you should administer the routine 28-week prophylaxis dose. The stakes are too high: without adequate prophylaxis, 17% of RhD-negative women become alloimmunized, risking severe HDFN in future pregnancies with potential fetal hydrops, intrauterine transfusions, and fetal death 1.